NL 201

Drug Profile

NL 201

Alternative Names: mIL-11; Mutein interleukin-11; NL 002; NL-201; VM-501

Latest Information Update: 21 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Northland Biotech
  • Developer Beijing Northland Biotech; ViroMed
  • Class Chemoprotectants; Interleukins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Haematopoiesis stimulants; Interleukin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombocytopenia

Highest Development Phases

  • Phase III Thrombocytopenia
  • Preclinical Blood coagulation disorders

Most Recent Events

  • 21 Jun 2016 Preclinical trials in Coagulation disorders in China (SC) before June 2016
  • 15 Feb 2016 NDR Project - ADS for ph III trial; added CTP for NCT01663441; as per Viromed website, ph III development is still ongoing (http://viromed.co.kr/main/sub02_01_3.html; http://viromed.co.kr/main/sub02_01.html; http://viromed.co.kr/main/sub02_02.html)
  • 15 Feb 2016 NL 201 is still in phase III development for Thrombocytopenia (chemotherapy-induced) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top